NanoString Technologies attracted $15.3 million in Series E financing, which it will use to advance the commercial launch of its debut breast cancer assay, navigate the U.S. regulatory approval process for its test and further its overall pipeline.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
There has been progress on the drug shortages front in the last few weeks with a couple of drugmakers saying manufacturing improvements have allowed them to again meet demand for two critical drugs. But as The New York Times points out, even with new drug shortages popping up at half the numbers of a year ago, there are still dozens of drugs in short supply.
The number of U.S. drugs that have been placed on a list of those in short supply is less than half what it was last year, only about 100 so far in 2012, compared with 221 when it peaked last year. The FDA says that it has prevented the shortage of about 150 drugs this year by working with the industry to find solutions to a potential dearth of a particular med.
Sanofi has plucked a chief scientific officer for its global R&D operations out of the top ranks at the National Institutes of Health. The pharma giant is placing him at an office in Cambridge, MA, highlighting once again its high hopes of reinventing drug research inside the rich scientific environment found in the booming Massachusetts biotech hub.
Genzyme's manufacturing improvements continue to pay off, allowing it to return to the market with a full supply of its thyroid cancer treatment, Thyrogen.
A drug shortage has been solved. Genzyme is now able to supply its thyroid cancer treatment, Thyrogen, even as it moves further into thyroid cancer treatment with a new biomarker that helps doctors determine the need for surgery.
Sanofi's Genzyme group in Boston put up a new set of data to back its bid to make Lemtrada a leading therapy for multiple sclerosis.
The French drugmaker's decision to open a new Fabrazyme plant is responsible for one of the few bright spots on their Q3 earnings report.
Sanofi ($SNY) CEO Christopher Viebacher wants you to look past this quarter to better times ahead. "We are seeing the light at the end of the tunnel," Viehbacher told the media, after announcing that third-quarter profits weren't as low as expected (as quoted by Reuters). Net income dropped 7.4% to €2.22 billion ($2.9 billion), when analysts had projected, on average, €1.97 billion ($2.55 billion).